CL2017002029A1 - Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08). - Google Patents

Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08).

Info

Publication number
CL2017002029A1
CL2017002029A1 CL2017002029A CL2017002029A CL2017002029A1 CL 2017002029 A1 CL2017002029 A1 CL 2017002029A1 CL 2017002029 A CL2017002029 A CL 2017002029A CL 2017002029 A CL2017002029 A CL 2017002029A CL 2017002029 A1 CL2017002029 A1 CL 2017002029A1
Authority
CL
Chile
Prior art keywords
streptococcus pneumoniae
impurities
production
cell lysates
soluble protein
Prior art date
Application number
CL2017002029A
Other languages
English (en)
Inventor
Yonghui Yuan
Mark Ruppen
Wei-Qiang Sun
Ling Chu
John Simpson
James Patch
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of CL2017002029A1 publication Critical patent/CL2017002029A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Se describe un proceso abreviado para producir una solución que contiene polisacáridos capsulares esencialmente purificados a partir de un caldo de lisado celular de Streptococcus pneumoniae. La ultrafiltración de un lisado clarificado de S. pneumoniae, seguido por ajuste del pH hasta menos de 4, 5, preferiblemente más o menos 3, 5, precipitó por lo menos 98% de la proteína contenida en la solución sin afectar seriamente al rendimiento de polisacárido. Además, después de la ultrafiltración y diafiltración y acidificación hasta un pH de menos de 4, 5, la filtración utilizando carbono activado precipitó por 10 menos 90% de la proteína restante sin afectar seriamente el rendimiento del polisácarido. Ejemplos de serotipos no limitativos de S. pneumoniae que pueden ser purificados utilizando el proceso abreviado de la invención son 1, 4, 5, 6, 6A, 7F, 9V, 14, 18C, 19A y 23F. </p>
CL2017002029A 2007-03-23 2017-08-08 Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08). CL2017002029A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23

Publications (1)

Publication Number Publication Date
CL2017002029A1 true CL2017002029A1 (es) 2018-05-18

Family

ID=39712482

Family Applications (2)

Application Number Title Priority Date Filing Date
CL200800831A CL2008000831A1 (es) 2007-03-23 2008-03-20 Procesos para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la produccion de polisacaridos neumococales.
CL2017002029A CL2017002029A1 (es) 2007-03-23 2017-08-08 Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL200800831A CL2008000831A1 (es) 2007-03-23 2008-03-20 Procesos para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la produccion de polisacaridos neumococales.

Country Status (29)

Country Link
US (3) US8652480B2 (es)
EP (3) EP3406635B1 (es)
JP (5) JP5688902B2 (es)
KR (2) KR101500771B1 (es)
CN (1) CN101663327B (es)
AU (1) AU2008231041B2 (es)
BR (1) BRPI0809212B8 (es)
CA (1) CA2681570C (es)
CL (2) CL2008000831A1 (es)
CO (1) CO6251324A2 (es)
CR (1) CR11041A (es)
DK (3) DK3406635T3 (es)
EC (1) ECSP099652A (es)
ES (3) ES2922132T3 (es)
GT (1) GT200900249A (es)
HN (1) HN2009001965A (es)
HU (3) HUE059085T2 (es)
IL (1) IL201106A (es)
MX (1) MX2009010221A (es)
MY (1) MY150927A (es)
NI (1) NI200900172A (es)
NZ (1) NZ580134A (es)
PL (3) PL2436700T3 (es)
PT (3) PT2436700T (es)
RU (1) RU2516340C2 (es)
SI (3) SI2129693T1 (es)
UA (1) UA99278C2 (es)
WO (1) WO2008118752A2 (es)
ZA (1) ZA200906625B (es)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059085T2 (hu) * 2007-03-23 2022-10-28 Wyeth Llc Streptococcus pneumoniae tokpoliszacharidok elõállítására szolgáló rövidített tisztítási eljárás
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
HUE029265T2 (en) * 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
KR101593770B1 (ko) * 2008-12-18 2016-02-15 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
AU2009335824B2 (en) * 2008-12-18 2013-07-04 Wyeth Llc Method for controlling Streptococcus pneumoniae polysaccharide molecular weight using carbon
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RU2536981C9 (ru) 2009-06-22 2015-05-10 ВАЙЕТ ЭлЭлСи Иммуногенные композиции антигенов staphylococcus aureus
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
WO2012127485A1 (en) * 2011-03-22 2012-09-27 Serum Institute Of India Ltd. A novel process for preparation of polysaccharides
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
WO2014038879A1 (ko) * 2012-09-07 2014-03-13 에스케이케미칼주식회사 폐렴 구균 혈청형을 갖는 협막 다당류의 제조방법
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
JP2016529885A (ja) 2013-07-12 2016-09-29 イー・エム・デイー・ミリポア・コーポレイシヨン 活性炭を使用して標的タンパク質を含む試料からのウイルス除去を決定する方法
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
ES2883343T3 (es) 2014-01-21 2021-12-07 Pfizer Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos
IL296681B2 (en) 2014-01-21 2024-09-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20160324949A1 (en) 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
FI3244917T3 (fi) 2015-01-15 2023-05-25 Pfizer Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
TWI807252B (zh) 2015-05-04 2023-07-01 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣-蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
JPWO2016204265A1 (ja) * 2015-06-18 2018-06-14 一般財団法人阪大微生物病研究会 肺炎球菌補体依存性殺菌能測定方法
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
HUE059252T2 (hu) 2017-01-20 2022-11-28 Pfizer Immunogén készítmények pneumokokkusz vakcinákban történõ alkalmazásra
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
HRP20251619T1 (hr) 2017-02-24 2026-02-13 Merck Sharp & Dohme Llc Formulacije pneumokoknih konjugiranih cjepiva
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 创赏公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
EP3649247A4 (en) 2017-07-05 2021-03-31 Inventprise, LLC. PURIFICATION OF POLYSACCHARIDES FOR VACCINE PRODUCTION USING LYTIC ENZYMES, TANGENTIAL FILTRATION AND MULTIMODAL CHROMATOGRAPHY
LT3678654T (lt) 2017-09-07 2024-08-26 Merck Sharp & Dohme Llc Pneumokokiniai polisacharidai ir jų panaudojimas imunogeninėse polisacharido ir baltymo nešiklio konjugatuose
KR102734995B1 (ko) 2017-09-07 2024-11-26 머크 샤프 앤드 돔 엘엘씨 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
EA202091382A1 (ru) 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
IL276230B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN111757754B (zh) 2018-02-05 2024-07-05 赛诺菲巴斯德有限公司 多价肺炎球菌多糖-蛋白质缀合物组合物
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
EP3787674A4 (en) 2018-04-30 2022-01-26 Merck Sharp & Dohme Corp. PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
AU2019299836B2 (en) 2018-07-04 2025-08-21 Vaxcyte, Inc. Improvements in immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
MX2021000548A (es) * 2018-07-19 2021-07-02 Glaxosmithkline Biologicals Sa Procesos para preparar polisacáridos en seco.
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP4003410A1 (en) 2019-07-31 2022-06-01 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US12473379B2 (en) * 2019-09-06 2025-11-18 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
JP7814103B2 (ja) * 2020-02-21 2026-02-16 ファイザー・インク 糖の精製
EP4165057A1 (en) * 2020-06-12 2023-04-19 Basf Se Improved demineralization of fermentation broths and purification of fine chemicals such as oligosaccharides
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
WO2022043855A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
EP4232593A1 (en) 2020-10-22 2023-08-30 Pfizer Inc. Methods for purifying bacterial polysaccharides
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234405A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2022249106A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202306969A (zh) 2021-05-28 2023-02-16 美商輝瑞大藥廠 包含結合之莢膜醣抗原的免疫原組合物及其用途
JP2025508749A (ja) 2022-01-13 2025-04-10 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
US20250163484A1 (en) 2022-02-25 2025-05-22 Pfizer Inc. Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
EP4626405A1 (en) 2022-12-01 2025-10-08 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
EP4701656A1 (en) 2023-04-24 2026-03-04 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2026505682A (ja) 2023-05-18 2026-02-18 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌ワクチンに有用な化合物およびアジュバント製剤
KR20260015203A (ko) 2023-05-19 2026-02-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 호흡기 세포융합 바이러스 및 스트렙토코쿠스 뉴모니아에 감염에 대한 면역 반응을 유발하는 방법
AU2024340201A1 (en) 2023-09-14 2026-03-19 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002004B1 (en) 1977-11-07 1982-03-24 Ciba-Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状（１→２）−β−Ｄ−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
CA2316975C (en) * 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) * 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
MX2007012337A (es) * 2005-04-08 2007-11-21 Wyeth Corp Separacion de contaminantes de polisacarido de streptococcus pneumoniae por manipulacion de ph.
HUE059085T2 (hu) * 2007-03-23 2022-10-28 Wyeth Llc Streptococcus pneumoniae tokpoliszacharidok elõállítására szolgáló rövidített tisztítási eljárás

Also Published As

Publication number Publication date
JP2020169160A (ja) 2020-10-15
ES2922132T3 (es) 2022-09-08
HUE059085T2 (hu) 2022-10-28
CL2008000831A1 (es) 2008-07-04
HUE031567T2 (hu) 2017-07-28
BRPI0809212B1 (pt) 2019-06-18
DK3406635T3 (da) 2022-05-30
PT3406635T (pt) 2022-07-08
US20080286838A1 (en) 2008-11-20
EP2129693B1 (en) 2016-12-07
IL201106A (en) 2014-04-30
US8999697B2 (en) 2015-04-07
JP6872649B2 (ja) 2021-05-19
PT2129693T (pt) 2017-02-14
MY150927A (en) 2014-03-14
US20140363463A1 (en) 2014-12-11
EP2436700A1 (en) 2012-04-04
JP2015143225A (ja) 2015-08-06
ECSP099652A (es) 2009-10-30
US8652480B2 (en) 2014-02-18
KR20100015765A (ko) 2010-02-12
EP2436700B8 (en) 2018-08-01
WO2008118752A3 (en) 2008-11-20
ES2614249T3 (es) 2017-05-30
MX2009010221A (es) 2009-10-19
DK2129693T3 (en) 2017-02-13
HUE039169T2 (hu) 2018-12-28
WO2008118752A2 (en) 2008-10-02
RU2516340C2 (ru) 2014-05-20
BRPI0809212B8 (pt) 2021-05-25
PL2436700T3 (pl) 2018-12-31
ES2677353T3 (es) 2018-08-01
HK1141815A1 (en) 2010-11-19
AU2008231041B2 (en) 2013-03-07
AU2008231041A8 (en) 2009-11-12
CA2681570A1 (en) 2008-10-02
ZA200906625B (en) 2010-07-28
EP3406635A1 (en) 2018-11-28
JP6825950B2 (ja) 2021-02-03
KR20150021127A (ko) 2015-02-27
ES2677353T8 (es) 2018-09-25
SI2129693T1 (sl) 2017-01-31
SI2436700T1 (sl) 2018-09-28
RU2009135485A (ru) 2011-04-27
AU2008231041A1 (en) 2008-10-02
IL201106A0 (en) 2010-05-17
JP2017141263A (ja) 2017-08-17
EP2129693A2 (en) 2009-12-09
JP5688902B2 (ja) 2015-03-25
US9675681B2 (en) 2017-06-13
HN2009001965A (es) 2011-10-06
US20150165017A1 (en) 2015-06-18
NI200900172A (es) 2010-09-07
CR11041A (es) 2009-12-30
EP2436700B1 (en) 2018-06-20
JP2019048844A (ja) 2019-03-28
DK2436700T3 (en) 2018-08-13
NZ580134A (en) 2011-10-28
CN101663327A (zh) 2010-03-03
CA2681570C (en) 2016-05-03
PT2436700T (pt) 2018-07-17
EP3406635B1 (en) 2022-05-11
PL2129693T3 (pl) 2017-07-31
CO6251324A2 (es) 2011-02-21
KR101500771B1 (ko) 2015-03-18
PL3406635T3 (pl) 2022-08-22
SI3406635T1 (sl) 2022-08-31
DK2436700T5 (en) 2018-09-03
CN101663327B (zh) 2014-05-07
GT200900249A (es) 2010-07-28
BRPI0809212A2 (pt) 2014-09-02
JP2010521972A (ja) 2010-07-01
UA99278C2 (ru) 2012-08-10

Similar Documents

Publication Publication Date Title
CL2017002029A1 (es) Proceso para extraer exceso de proteina soluble e impurezas a partir de lisados celulares de serotipos de streptococcus pneumoniae utilizados en la producción de polisacaridos neumococales (divisional de sol. n°831-08).
ES2651415T3 (es) Método de producción de un polisacárido capsular que tiene un serotipo neumocócico
MX2009003730A (es) Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.
MX2015006455A (es) Produccion de altos rendimientos de polisacaridos bacteriales.
CN103044457B (zh) 头孢他啶纯化方法
RU2018135066A (ru) Новые конъюгаты полисахарида с белком и способ их получения
US8398985B2 (en) Antigenic polysaccharides and process for their preparation
WO2009056707A3 (fr) Dérivés de l&#39;ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique
CN104974276A (zh) 琥珀酸酐环糊精的制备方法
WO2003105906A8 (en) A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
TW200728282A (en) Method for making nicotine hapten
US11395844B2 (en) Pueraria flower extract rich in isoflavones and a method and application of the same
KR20180120482A (ko) 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
CN1876659B (zh) 完全没有溶剂的酸头孢替坦和获得它的方法
Kim The transition of the indigo dyeing method identified through the agricultural archives in the latter Joseon dynasty
TW201522622A (zh) 用於製備肺炎鏈球菌血清型之莢膜多醣的方法
Borjihan Biomedical activities of derivatives of polysaccharides extracted from astragalus membranaceus